Addendum
Durvalumab (urothelial carcinoma) – Addendum to Project A25-97
Report documents
-
Addendum
Durvalumab (Urothelkarzinom) – Addendum zum Projekt A25-97
Dossier assessment
Indication:
Adults with resectable muscle-invasive bladder cancer (MIBC) for whom platinum-based chemotherapy is suitable; neoadjuvant and adjuvant therapy after radical cystectomy
Additional information
Federal Joint Committee (G-BA)
22-01-2026 A G-BA decision was published.
G-BA documents on this decision
Project details
- Project no.
- A25-151
- Commission
- Commission awarded on 09.12.2025 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
- DOI
https://doi.org/10.60584/A25-151_en
Connected Projects
-
Dossier assessment
Durvalumab (urothelial carcinoma) – Benefit assessment according to § 35a SGB V
Status: Commission completed